Author

Carlos L. Arteaga

Harold C. Simmons Comprehensive Cancer CenterORCID 0000-0003-0870-9586Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:Bayesian inference· 1 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Ariella B. HankeriD· 2 shared Ping MuiD· 2 shared Tao WangiD· 2 shared Yunguan WangiD· 2 shared Alicia MalewskaiD· 1 shared Atreyi MukherjiiD· 1 shared Carla R. TiradoiD· 1 shared Choushi WangiD· 1 shared

Activity by Year

2024-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

Ariella B. HankerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioinformaticsNature MethodsPeer-reviewedSep 3, 2024

Mapping Cell-to-cell Interactions from Spatially Resolved Transcriptomics Data

James J. Zhu, Yunguan Wang, Woo Yong Chang…·Tao Wang

The paper introduces a Bayesian framework to map cell-cell interactions from spatial transcriptomics data, revealing new biological insights in cancer and immune responses.

74 citationstop 1%

humanspatial transcriptomics

𝕏 PostBluesky

Cancer BiologyCancer DiscoveryPeer-reviewedApr 8, 2024

ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers

Yaru Xu, Yuqiu Yang, Zhaoning Wang…·Ping Mu

This study shows ZNF397 loss leads to TET2-driven epigenetic changes, lineage plasticity, and resistance to AR-targeted therapies in AR-dependent cancers, with TET2 inhibitors reversing resistance.

50 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky